PROJECT TITLE: EFFECTS OF ATORVASTATIN ON BLOOD PRESSURE AND URINARY ALBUMIN EXCRETION IN PATIENTS WITH ESSENTIAL HYPERTENSION - ST.A.Y

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2006-001669-41-GR

Enrollment

Registered

2006-11-24

Start date

2007-05-08

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

50 patients with hypertension and newly diagnosed mild hypercholesterolemia. MedDRA version: 8.1 Classification code 10062060

Interventions

Trade Name: LIPITOR Product Name: Lipitor Product Code: NA Pharmaceutical Form: Tablet Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Pharmaceutical form of th

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.LDL-C>130 or >160 mg/dL (depending on the total risk according to the most recent recommendations25). 2. no previous hypolipidemic medication 3. ability to provide Informed Consent. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. pregnancy or lactation 2. myocardial infarction or unstable angina within the past 6 months 3. heart failure NYHA class III-IV 4. renal disease (SCr>3 mg/dL or proteinuria>3g/d) 5. liver disease 6. history of malignancy 7. history of drug or alcohol abuse 8. treatment with corticosteroids 9. any other condition with poor prognosis 10. inability to provide Informed Consent.

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile. Glycemic parameters, “novel” cardiovascular risk factors and safety parameters will be also evaluated.;Secondary Objective: ;Primary end point(s): Basic measures: 1) ambulatory blood pressure	—

Measure

Time frame

Main Objective: To evaluate the possible effects of atorvastatin on ambulatory blood pressure, urinary albumin excretion, insulin resistance and arterial stiffness in hypertensive patients, beyond those on lipid profile. Glycemic parameters, “novel” cardiovascular risk factors and safety parameters will be also evaluated.;Secondary Objective: ;Primary end point(s): Basic measures: 1) ambulatory blood pressure

—

Countries

Greece

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026